维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

6篇 您的检索式：作者名="Mark D. Lim"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Longitudinal Studies of a B Cell–Derived Signature of Tolerance in Renal Transplant Recipients显示文摘	K. A. Newell A. Asare I. Sanz C. Wei A. Rosenberg Z. Gao S. Kanaparthi S. Asare N. Lim M. Stahly M. Howell S. Knechtle A. Kirk W. H. Marks T. Kawai T. Spitzer N. Tolkoff‐Rubin M. Sykes D. H. Sachs A. B. Cosimi W. J. Burlingham D. Phippard L. A. Turka	2015	American Journal of Transplantation2015，，11：	1
	2	Florbetapir F-18: A Histopathologically Validated Beta-Amyloid Positron Emission Tomography Imaging Agent显示文摘	John Lister-James Michael J. Pontecorvo Chris Clark Abhinay D. Joshi Mark A. Mintun Wei Zhang Nathaniel Lim Zhiping Zhuang Geoff Golding Seok Rye Choi Tyler E. Benedum Paul Kennedy Franz Hefti Alan P. Carpenter Hank F. Kung Daniel M. Skovronsky	2011	Seminars in Nuclear Medicine2011，，：	1
	3	Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children显示文摘	Elizabeth T. Schaefer Joseph F. Fitzgerald Jean P. Molleston Joseph M. Croffie Marian D. Pfefferkorn Mark R. Corkins Joel D. Lim Steven J. Steiner Sandeep K. Gupta	2008	Clinical Gastroenterology and Hepatology2008，，：	1
	4	Molecular phylogenetic analysis of the Grey-cheeked Fulvetta ( Alcippe morrisonia ) of China and Indochina: A case of remarkable genetic divergence in a “species”显示文摘	Fasheng Zou Haw Chuan Lim Ben D. Marks Robert G. Moyle Frederick H. Sheldon	2006	Molecular Phylogenetics and Evolution2006，，：	1
	5	Preoperative evaluation of pancreatic cystic lesions: Cost-benefit analysis and proposed management algorithm显示文摘	Sherry J. Lim Rameez Alasadi Jeffrey D. Wayne Sam Rao Alfred Rademaker Richard Bell Mark S. Talamonti	2005	Surgery2005，，4：	1
	6	Philanthropies as partners for drug development in public-private partnerships显示文摘Disease-focused philanthropic organizations play an increasing role in the strategy and conduct of biomedical research, with many focusing on drug development for specific diseases and patient populations. More and more they not only provide resources and expertise, but also take active part managing the strategy and objectives of targeted research programs, using approaches such as venture philanthropy. Many also lead and participate in public-private partnerships. One example is the partnership between the Polycystic Kidney Disease (PKD) Foundation and the Critical Path Institute (C-Path) which brings together several pharmaceutical companies and academic institutions to develop new broadly-used biomarkers. Another case is the partnership between JDRF (formerly known as the Juvenile Diabetes Research Foundation) and the Innovative Medicines Initiative (IMI), involving financial support of the IMIDIA project (Innovative Medicines Initiative for Diabetes) which is focused on improving beta-cell function and identifying biomarkers for diabetes treatment monitoring. These examples show that in addition to providing financial support and expertise, philanthropic foundations are also in a unique position to coordinate the patient and research communities to enable and accelerate specific medicines development projects.	Mark D. Lim Martha A. Brumfield Michel Goldman	2015	Journal of Medicines Development Sciences2015，1，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费